Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Raw Materials: 2016-2025

Historic Raw Materials for Adma Biologics (ADMA) over the last 8 years, with Sep 2025 value amounting to $87.8 million.

  • Adma Biologics' Raw Materials rose 58.99% to $87.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.8 million, marking a year-over-year increase of 58.99%. This contributed to the annual value of $60.5 million for FY2024, which is 14.10% up from last year.
  • Latest data reveals that Adma Biologics reported Raw Materials of $87.8 million as of Q3 2025, which was down 12.49% from $100.4 million recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Raw Materials registered a high of $100.4 million during Q2 2025, and its lowest value of $33.1 million during Q2 2021.
  • Moreover, its 3-year median value for Raw Materials was $57.0 million (2024), whereas its average is $64.1 million.
  • Data for Adma Biologics' Raw Materials shows a peak YoY skyrocketed of 76.14% (in 2025) over the last 5 years.
  • Adma Biologics' Raw Materials (Quarterly) stood at $36.8 million in 2021, then spiked by 32.34% to $48.6 million in 2022, then climbed by 8.95% to $53.0 million in 2023, then rose by 14.10% to $60.5 million in 2024, then soared by 58.99% to $87.8 million in 2025.
  • Its Raw Materials was $87.8 million in Q3 2025, compared to $100.4 million in Q2 2025 and $75.8 million in Q1 2025.